Orchid Chemicals procures USFDA approval for Cephalexin
By Our Corporate Bureau | 11 Nov 2002
Chennai:
The
city-based Cephalosporin bulk drug major Orchid Chemicals
and Pharmaceuticals today announced that Cephalexin, its
flagship product manufactured in its Alathur bulk drug
facility, has gone through the US Food and Drugs Administration
(USFDA) audit successfully.
A formal communication from USFDA certifying the product is expected soon once due formalities are completed at their end.
Says Orchid managing director K Raghavendra Rao: “Coming at a time when Orchid is making significant investments in new USFDA-compliant plants and processes, and is strongly working towards an entry into regulated markets with a wide range of our Cephalosporin products, this is definitely going to provide us with a great impetus.”